Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44393   clinical trials with a EudraCT protocol, of which   7405   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,393 result(s) found. Displaying page 488 of 2,220.
    «« First « Previous 484  485  486  487  488  489  490  491  492  Next» Last»»
    EudraCT Number: 2010-018630-52 Sponsor Protocol Number: IC51-315 Start Date*: 2010-05-27
    Sponsor Name:Intercell AG
    Full Title: AN OPEN-LABEL, UNCONTROLLED PHASE 4 STUDY TO ASSESS THE SAFETY AND IMMUNOGENICITY OF THE JAPANESE ENCEPHALITIS (JE) VACCINE IXIARO® (IC51) IN AN ELDERLY POPULATION
    Medical condition: IXIARO® is used to protect adults against Japanese encephalitis (JE). JE can be fatal or lead to long-term disability. Vaccination with Ixiaro should be considered for people who are at risk of exp...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10014596 Encephalitis Japanese B LLT
    12.1 10023119 Japanese B encephalitis LLT
    12.1 10023120 Japanese B viral encephalitis LLT
    12.1 10023122 Japanese B virus encephalitis LLT
    12.1 10023123 Japanese encephalitis LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2010-023948-33 Sponsor Protocol Number: 6038-PR-PRI-181 Start Date*: 2011-08-16
    Sponsor Name:LABORATORIOS LETI, S.L. UNIPERSONAL
    Full Title:
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021428 - Immune system disorders 10036019 Pollen allergy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-006295-11 Sponsor Protocol Number: ICOG-2007 Start Date*: 2008-04-07
    Sponsor Name:Instituto de Investigación del Hospital de la Santa Creu i Sant Pau
    Full Title: TREATMENT OF PRIMARY ACUTE MYELOID LEUKEMIA WITH THE COMBINATION OF IDARUBICIN, CYTARABINE AND GEMTUZUMAB OZOGAMYCIN (MYLOTARG) ASSOCIATED OR NOT TO G-CSF PRIMING: PROSPECTIVE STUDY OF EFFICACY AND...
    Medical condition: Leucemia Mieloide Aguda Primaria "de novo"
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000886 Acute myeloid leukemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-017245-64 Sponsor Protocol Number: OG09/9146 Start Date*: 2010-09-07
    Sponsor Name:Leeds Teaching Hospitals NHS Trust
    Full Title: The effect of metformin co-treatment in hormone-replacement frozen embryo replacement cycles in women with polycystic ovary syndrome.
    Medical condition: Polycystic Ovary Syndrome
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-020977-18 Sponsor Protocol Number: 214868-002 Start Date*: 2010-10-06
    Sponsor Name:Allergan Ltd
    Full Title: A Multicenter, Double-blind, Randomized, Placebo-controlled, Repeat Treatment (two cycle) Study of the Safety and Efficacy of AGN-214868 in Patients with Postherpetic Neuralgia
    Medical condition: Phase II study to investigate the safety and efficacy of AGN-214868 compared to placebo in the treatment of postherpetic neuralgia The study will look at patients with postherpetic neuralgia (PHN...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10054095 Neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-017178-19 Sponsor Protocol Number: GFM- Aza-Ida-09 Start Date*: 2010-09-14
    Sponsor Name:Groupe Francophone des Myélodysplasies
    Full Title: A phase I-II study of the efficacy and safety of Idarubicin combined to Azacitidine in int-2 or high risk myelodysplastic syndromes
    Medical condition: Myelodysplastic syndromes
    Disease: Version SOC Term Classification Code Term Level
    12.1 10028533 Myelodysplastic syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-024473-39 Sponsor Protocol Number: CINC424A2401 Start Date*: 2011-06-22
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, multicenter, expanded access study of INC424 for patients with primary myelofibrosis (PMF) of post polycythemia vera myelofibrosis (PPV MF) or post-essential thrombocythemia myelofib...
    Medical condition: primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (PPV MF) or Post essential thrombocythemia myelofibrosis (PET-MF)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Completed) BE (Completed) DE (Completed) ES (Completed) GR (Completed) HU (Completed) PT (Completed) SK (Completed) PL (Completed) IT (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2010-024477-39 Sponsor Protocol Number: 105MS302 Start Date*: 2011-05-06
    Sponsor Name:Biogen Idec Limited
    Full Title: A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) BE (Completed) DE (Completed) ES (Completed) BG (Completed) EE (Completed) GB (Completed) GR (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2009-015086-31 Sponsor Protocol Number: Ten03 Start Date*: 2010-03-16
    Sponsor Name:Bio Products Laboratory Limited
    Full Title: Ten03: A Phase III Open, Multicentre Study to Investigate the Safety and Efficacy of BPL’s High Purity Factor X in the treatment of the Factor X Deficient Subjects Undergoing Surgery
    Medical condition: Factor X Deficiency
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-001363-46 Sponsor Protocol Number: ML25739 Start Date*: 2011-08-22
    Sponsor Name:ROCHE
    Full Title: RANDOMIZED, NON COMPARATIVE PHASE II TRIAL WITH BEVACIZUMAB AND FOTEMUSTINE IN THE TREATMENT OF RECURRENT GLIOBLASTOMA.
    Medical condition: Glioblastoma multiforme progressed after a first line treatment with temozolomide and radiotherapy.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-001371-39 Sponsor Protocol Number: MP4006 Start Date*: 2011-03-30
    Sponsor Name:Meda Pharmaceuticals Inc.
    Full Title: Randomized, Double-Blind Trial of MP29-02 Nasal Spray Compared to Placebo, Azelastine Hydrochloride Nasal Spray and Fluticasone Propionate Nasal Spray in the Treatment of Patients with Seasonal All...
    Medical condition: treatment of seasonal allergic rhinitis
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038738 - Respiratory, thoracic and mediastinal disorders 10039776 Seasonal allergic rhinitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-001382-40 Sponsor Protocol Number: Metform01 Start Date*: 2011-09-09
    Sponsor Name:Central Manchester University Hospitals NHS Foundation Trust
    Full Title: Proof of mechanism pre-surgical window trial of metformin in non-diabetic women with endometrial carcinoma: a feasibility study
    Medical condition: Endometrial carcinoma or hyperplasia
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014733 Endometrial cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-002022-41 Sponsor Protocol Number: CHAGAS-EVOL I Start Date*: 2011-10-13
    Sponsor Name:Fundación para la Investigación Biomédica del Hospital Ramón y Cajal
    Full Title: Assessment of Therapeutic Response to Benznidazole in patients with Chronic Chagas Disease by Measuring Plasma Parasite Load and the Specific Immune Response against Trypanosoma cruzi. A Randomized...
    Medical condition: Chagas disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10008384 Chagas' disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002029-24 Sponsor Protocol Number: AX11 Start Date*: 2011-04-19
    Sponsor Name:UNIVERSITA' CAMPUS BIOMEDICO
    Full Title: MULTICENTER SECOND LINE STUDY OF AXITINIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) PROGRESSED WITH SORAFENIB
    Medical condition: Hepatocellular carcinoma (HCC)
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002052-14 Sponsor Protocol Number: EURO-HIT-HLH Start Date*: 2011-06-07
    Sponsor Name:AZIENDA OSPEDALIERA MEYER
    Full Title: EURO-HIT-HLH European cooperative pilot study for testing Hybrid ImmunoTherapy for Hemophagocytic LymphoHistiocytosis
    Medical condition: Familial hemophagoytic lymphohistiocytosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10005329 Blood and lymphatic system disorders SOC
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002061-38 Sponsor Protocol Number: S53299 Start Date*: 2011-06-29
    Sponsor Name:Katholieke Universiteit Leuven
    Full Title: A randomised prospective trough level monitoring study with real-time therapeutic adaptations: Trough level Adapted infliXImab Treatment scheme (TAXIT).
    Medical condition: 2) Crohn's disease and ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    13.1 10017947 - Gastrointestinal disorders 10045365 Ulcerative colitis LLT
    13.1 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001821-26 Sponsor Protocol Number: SP2 Start Date*: 2011-10-18
    Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO
    Full Title: Aerosol Tobramycin 300 mg single dose in adult patient with cystic fibrosis: pilot study of antimicrobial activity
    Medical condition: Adult patient with cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-001836-44 Sponsor Protocol Number: UCL/11/0119 Start Date*: 2012-06-11
    Sponsor Name:University College London
    Full Title: A Phase II Trial to Assess the Activity of TroVax® (MVA-5T4) Versus Placebo in Patients with Relapsed Asymptomatic Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
    Medical condition: Patients with relapsed asymptomatic epithelial ovarian, fallopian tube or primary peritoneal cancer
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004148-23 Sponsor Protocol Number: 1218.22 Start Date*: 2013-10-04
    Sponsor Name:Boehringer Ingelheim International GmbH
    Full Title: A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients...
    Medical condition: Diabetes Mellitus type 2
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) GB (Completed) CZ (Completed) NL (Completed) HU (Completed) ES (Completed) PL (Completed) BG (Completed) HR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-000989-35 Sponsor Protocol Number: P101001 Start Date*: Information not available in EudraCT
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title:
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    14.0 10010331 - Congenital, familial and genetic disorders 10066131 Congenital central hypoventilation syndrome PT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 484  485  486  487  488  489  490  491  492  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Apr 03 13:31:25 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA